Oasis Petroleum Inc. (NYSE:OAS)

Oasis Petroleum Inc. is an independent exploration and production company focused on the acquisition and development of oil and natural gas resources. The Company is currently focused on exploiting resource potential from the Bakken and Three Forks formations, which are present across a substantial majority of its acreage. Oasis Petroleum Inc. is based in Houston, Texas.

Oasis Petroleum Inc. (NYSE:OAS)’s Financial Overview

Oasis Petroleum Inc. (NYSE:OAS) surged 27.73% yesterday to close its trading session at $14.97. The company has 1 year Price Target of $14.54. Oasis Petroleum Inc. has 52-Week high of $15.02 and 52-Week Low of $3.4. The stock touched its 52-Week High on Nov 22, 2016 and 52-Week Low on Jan 20, 2016. The stock traded with the volume of 34.18 Million shares yesterday. The firm shows the market capitalization of $3.54 Billion.

Oasis Petroleum Inc. (NYSE:OAS) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.17/share against the analyst consensus estimate of $-0.19/share. The difference between the actual and expected EPS is $0.02 a share with a surprise factor of 10.5%.

The firm is trading with SMA20 of 27.06 Percent, SMA50 of 32.89 Percent and SMA200 of 60.47 percent. Oasis Petroleum Inc. has P/S value of 5.29 while its P/B value stands at 1.11. Similarly, the company has Return on Assets of -3.3 percent, Return on Equity of -7.8 percent and Return on Investment of -2.1 Percent. The company shows Gross Margin and Operating Margin of 67.7 percent and -26.5 percent respectively.

Many brokerage firms are involved in issuing their ratings on Oasis Petroleum Inc. (NYSE:OAS). On 9-Nov-16 Wunderlich Upgrade Oasis Petroleum Inc. Stock  to Buy. Another firm also rated the stock on 20-Oct-16 where Tudor Pickering Upgrade the stock to Buy.

The Stock currently has Analyst’ mean Recommendation of 2.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 33 analysts offering 12-month price forecasts for Oasis Petroleum Inc have a median target of 14.00, with a high estimate of 21.00 and a low estimate of 8.00. The median estimate represents a -6.48% decrease from the last price of 14.97.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Horizon Pharma plc (NASDAQ:HZNP)

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.

Horizon Pharma plc (NASDAQ:HZNP)’s Financial Outlook

The 11 analysts offering 12-month price forecasts for Horizon Pharma PLC have a median target of 30.00, with a high estimate of 45.00 and a low estimate of 23.00. The median estimate represents a +51.52% increase from the last price of 19.80.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Horizon Pharma plc has a Consensus Recommendation of 1.29. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -5.94% and closed its last trading session at $19.8. The company has the market capitalization of $3.19 Billion. The stock has 52-week high of $23.44 and 52-Week low of $13.05. The firm touched its 52-Week high on Aug 15, 2016 and 52-Week low on May 6, 2016. The company has volume of 5.14 Million shares. The company has a total of 161.26 Million shares outstanding.

Horizon Pharma plc (NASDAQ:HZNP) in the last quarter reported its actual EPS of $0.7/share where the analyst estimated EPS was $0.63/share. The difference between the actual and Estimated EPS is $0.07. This shows a surprise factor of 11.1 percent.

The company has YTD performance of -8.63 percent. Beta for Horizon Pharma plc stands at 1.8 while its ATR (average true range) is 1.01. The company has Weekly Volatility of 5.17%% and Monthly Volatility of 5.65%%.

Horizon Pharma plc has distance from 20-day Simple Moving Average (SMA20) of 1.5%, Distance from 50-Day Simple Moving Average of 5.2 percent and Distance from 200-Day Simple Moving Average of 10.53%.

The Company currently has ROA (Return on Assets) of -0.4 percent, Return on Equity (ROE) of -0.9 Percent and Return on Investment (ROI) of 3% with Gross margin of 66 percent and Operating & Profit margin of -6.2% and -1.3% respectively.